Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Share:
Related BMY
Technical Alert: Bristol-Myers Squibb Makes New For Move
Brean Downgrades The Healthcare Sector On Technical Indicators
Revamping My Dividend Growth Portfolio (Seeking Alpha)
Related MRK
The 2015 Flash Crash Was One Year Ago Today. Why Did It Happen?
Write A Prescription For More Pharma M&A With This ETF
Parsabiv NDA Fails; Implications For Amgen (Seeking Alpha)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
Aug 2016UBSMaintainsBuy
Aug 2016BerenbergDowngradesBuyHold
Aug 2016Deutsche BankMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!